Brief: US FDA Approves Avlayah To Treat Neurologic Manifestations Of Hunter Syndrome
Brief: Denali Therapeutics Announces U.S. FDA Approval Of Avlayah™ (Tividenofusp Alfa-Eknm) For Treatment Of Hunter Syndrome (Mps Ii)
US FDA approves Denali's genetic disorder therapy (updated)
US FDA approves Denali's genetic disorder therapy
Denali Therapeutics Q4 net loss deepens
Brief: Denali Therapeutics Q4 Operating Expenses USD 137.365 Million
Brief: Denali Therapeutics Announces Data Presentations On Enzyme Transportvehicle™ Programs For Hunter Syndrome, Sanfilippo Syndrome Type A And Pompe Disease At Upcoming 2026 Worldsymposium™
Brief: Denali Therapeutics Announces Key Anticipated Milestones And Priorities For 2026
Brief: Denali Therapeutics Says Co Prices Public Offering Of 9.14 Mln Shares At $17.50 Each
Denali Therapeutics slides after launching $200 million share sale
Brief: Denali Therapeutics And Royalty Pharma Announce $275 Million Royalty Funding Agreement
Denali Therapeutics Q3 net loss widens to $126.9 mln
Brief: Denali Therapeutics Q3 Operating Expenses USD 137.434 Million
U.S. RESEARCH ROUNDUP-Affiliated Managers Group, Argenx SE, Cardinal Health Inc
Brief: Denali Therapeutics Announces FDA Review Extension Of BLA For Tividenofusp Alfa
U.S. RESEARCH ROUNDUP-Apollo, Blackstone, Nvidia
Denali Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Denali Therapeutics Q2 Basic EPS USD -0.72
Denali Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary